Low-dose Methotrexate Therapy for Intravenous Immunoglobulin-resistant Kawasaki Disease
Yonsei Medical Journal
;
: 714-718, 2008.
Article
in English
| WPRIM
| ID: wpr-153707
ABSTRACT
PURPOSE:
The aim of this study was to evaluate the efficacy of low-dose oral methotrexate (MTX) as a treatment for patients with Kawasaki disease (KD) which was resistant to intravenous immunoglobulin (IVIG). PATIENTS ANDMETHODS:
The patients who had persistent or recrudescent fever after treatment with IVIG were subsequently treated with low-dose oral MTX [10mg/body surface area (BSA)] once weekly.RESULTS:
Seventeen patients developed persistent or recrudescent fever after treatment of KD with IVIG and were consequently given MTX. The proportion of children with coronary artery lesions (CALs) was 76%. The median value of maximum body temperatures decreased significantly within 24 hours of MTX therapy (38.6degrees C vs. 37.0degrees C, p < 0.001). The median CRP (C-reactive protein) level was found to be significantly lower 1 week after administering the first dose of MTX (8.9mg/dL vs. 1.2mg/dL, p < 0.001). The median duration of fever before MTX treatment was shorter in CALs (-) group than in CALs (+) group (7 days vs. 10 days, p = 0.023). No adverse effects of MTX were observed.CONCLUSION:
MTX treatment for IVIG-resistant KD resulted in quick resolution of fever and rapid improvement of inflammation markers without causing any adverse effects. MTX therapy should further be assessed in a multicenter, placebo-blinded trial to evaluate whether it also improves coronary artery outcome.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Drug Resistance
/
Methotrexate
/
Treatment Outcome
/
Immunoglobulins, Intravenous
/
Mucocutaneous Lymph Node Syndrome
Type of study:
Controlled clinical trial
Limits:
Child
/
Child, preschool
/
Female
/
Humans
/
Infant
/
Male
Language:
English
Journal:
Yonsei Medical Journal
Year:
2008
Type:
Article
Similar
MEDLINE
...
LILACS
LIS